300 results
424B3
KZIA
Kazia Therapeutics Limited
1 May 24
Prospectus supplement
4:06pm
to 500mg BID. In general, EVT801 was tolerated across all doses with the majority of toxicities being mild to moderate and transient in nature. Eleven
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
1 May 24
Kazia Reports Successful Stage 1 Completion of the EVT801
4:01pm
. In general, EVT801 was tolerated across all doses with the majority of toxicities being mild to moderate and transient in nature. Eleven different cancer
424B3
KZIA
Kazia Therapeutics Limited
19 Apr 24
Prospectus supplement
4:30pm
of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially … ) as a foreign company in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except
6-K
EX-4.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially
6-K
EX-10.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure … as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
424B3
7humn6vfjkp0x
27 Mar 24
Prospectus supplement
8:37am
6-K
EX-99.1
00vma csh
27 Mar 24
Current report (foreign)
8:26am
424B3
vatqf8aa
5 Feb 24
Prospectus supplement
4:19pm
F-1
81vh hwq73
31 Jan 24
Registration statement (foreign)
12:00am
F-1
EX-3.1
pygxkjz 0z8wq3
31 Jan 24
Registration statement (foreign)
12:00am
F-3
EX-4.3
gdxuk
15 Dec 23
Shelf registration (foreign)
5:26pm
F-3
d2nqu4i 6h
15 Dec 23
Shelf registration (foreign)
5:26pm
D
7oacopgk8cek8kyec
15 Dec 23
$2.00 mm in options / securities to be acquired, sold $2.00 mm, 1 investor
4:49pm
6-K
EX-10.1
lcl657zfptln 4p5
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
424B5
ld4x3 q300dw41f11uy
4 Dec 23
Prospectus supplement for primary offering
4:05pm
6-K
EX-99.1
gkflwnl6jt tt
29 Nov 23
Current report (foreign)
4:02pm
6-K
EX-99.2
wpgxnjjd94ica
13 Oct 23
Current report (foreign)
4:08pm
6-K
EX-99.3
b1v qbh80so
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.1
eiuwnmphem 1u
5 Sep 23
Current report (foreign)
7:02am